Skip to content
Search

Latest Stories

'Smoking causes depression and schizophrenia'

Smoking increases the risk of developing schizophrenia and depression, a report by academics from the University of Bristol published on 20 June claims.

It says smoking raises the risk of developing schizophrenia by between 53 per cent and 127 per cent and the risk of developing depression by from 54 per cent to 132 per cent.


The authors of the report say more research is needed to identify why this is the case and that more evidence is needed to understand its impact on other mental health conditions such as anxiety or bipolar disorder.

The evidence, presented at the Royal College of Psychiatrist's international congress, has been shared with the government which is currently developing a new Tobacco Control Plan for publication later this year.

Action on Smoking and Health (ASH) said: “Rates of smoking are much higher among people with mental health conditions than those without, and among England’s six million smokers there are an estimated 230k smokers with severe mental illness (e.g., schizophrenia and bi-polar disorder) and 1.6 million with depression and anxiety.”

These analyses are timely as the government is currently considering recommendations by the Khan Review for the forthcoming Tobacco Control Plan to deliver its 'smokefree 2030' ambition.

The independent review by Javed Khan was commissioned by the health secretary to help the government to identify the most impactful interventions to reduce the uptake of smoking, and support people to stop smoking, for good.

One of Khan’s 15 recommendations was that action is needed to tackle the issue of smoking and mental health.

Dr Adrian James, President of the Royal College of Psychiatrists, said: “Smoking addiction is not a trivial matter; it causes serious harm to both body and mind. Smokers with mental health conditions can quit with the right support from healthcare professionals. It’s our duty as psychiatrists to offer them the help they need to succeed.”

Joanne Hart, former smoker and recovered from depression, said: “Stopping smoking changed my life for the better, both physically and mentally. It is shocking to learn that smoking could have been one of the reasons for my depression. As a smoker I knew I was damaging my health but when times were tough it was easy to think that it was helping mentally – everyone should know the opposite is true.”

Deborah Arnott, chief executive, ASH, said: “The Khan Review is called ‘Making Smoking Obsolete’ – this cannot be achieved if we ignore the more than a million smokers with mental health conditions. While the NHS has started to roll out support to quit for those with severe mental illness there is little provision for those with common mental health conditions like depression and anxiety – a plan is needed.”

More For You

Pharmacist Support calls for birthday donations to meet rising demand for mental health services

More and more pharmacy professionals are reaching out for help, said Danielle Hunt.

Pharmacist Support's birthday appeal: Donate to address growing mental health demand

Pharmacist Support – the independent charity dedicated to the pharmacy profession – is celebrating 184 years of service with the launch of a special birthday donations appeal.

On 15 April, the charity is urging individuals and organisations across the sector to support its campaign to raise vital funds to meet the increasing demand for its mental health and wellbeing services.

Keep ReadingShow less
Prostate cancer: At-home saliva test could save NHS £500 million annually

PRS saliva test can identify prostate cancer that was missed by an MRI scan

Photo credit: gettyimages

Prostate cancer: Spit test better than blood test in spotting men at highest risk

A simple at-home spit test could help detect prostate cancer earlier, saving the NHS around £500 million a year, according to new research published in the New England Journal of Medicine.

Funded by the National Institute for Health and Care Research (NIHR), the study found that the DNA-based saliva test was more accurate than the current prostate-specific antigen (PSA) blood test in identifying men at risk of developing prostate cancer.

Keep ReadingShow less
RPS launches innovative new learning resources for members

With RPS Learn, pharmacists can develop a new skill or improve their understanding of practice or a clinical topic.

Gettyimages

RPS launches new learning resources to boost career development for members

The Royal Pharmaceutical Society (RPS) has launched a new online learning platform designed to support the practice, development and career advancement of its members.

The new platform, called RPS Learn, offers a diverse range of bite-size learning content, available on-demand, catering to all levels — from introductory to advanced and specialist —combining new content with RPS's renowned expertise in education and training to achieve excellence for learners.

Keep ReadingShow less
NICE approves AstraZeneca’s twice-a-day tablet ‘capivasertib’ for advanced breast cancer

HR-positive, HER2-negative advanced breast cancer is currently incurable, and treatment aims to slow progression and prolong life

Gettyimages

NICE approves twice-a-day tablet for advanced breast cancer

Every year, thousands of people with hormone receptor (HR)-positive HER2-negative breast cancer could benefit from a new twice-a-day tablet, now set to be funded immediately through the Cancer Drugs Fund.

The National Institute for Health and Care Excellence (NICE) has approved the use of capivasertib (also known as Truqap), in combination with fulvestrant, as an option for around 1,100 adults with HR-positive HER2-negative breast cancer that has certain genetic mutations and has spread.

Keep ReadingShow less
ABPI and government fast-track VPAG scheme review to address high medicine payment rates

The 2025 VPAG payment rate for newer medicines has been set at 22.9 per cent.

Photo credit: gettyimages

Review of 2024 VPAG scheme to be completed by June

The Association of the British Pharmaceutical Industry (ABPI) and the government have agreed to bring forward a planned review of the 2024 Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG), originally scheduled for autumn 2025.

The review is expected to be completed in June 2025, aligning with the anticipated release of the government’s 10-year NHS Plan and the Life Sciences Sector Plan as part of the broader industry strategy this summer.

Keep ReadingShow less